## Supplementary Material

 $Supplementary\ Table\ 1.\ List\ of\ symptom\ and\ comorbidity\ questions\ asked\ in\ the\ COVID\ Symptom\ Study\ application\ during\ the\ current\ study\ period.$ 

Symptom	COVID Symptom Study app question	Date of addition to the app	Symptom group	
Fever	Fever (at least 37.8C or 100F)	2020-03-29	Systemic/inflammatory	
Persistent Cough	A persistent cough (coughing a lot for more than an hour or 3 or more coughing episodes in 24 hours)	2020-03-29	Cardiorespiratory	
Fatigue	Unusual fatigue (no; mild fatigue; severe fatigue/ I struggle to get out of bed)	2020-03-29	Systemic/inflammatory	
Dyspnoea	Shortness of breath or trouble breathing (no; yes mild symptoms/ slight shortness of breath during ordinary activity: yes significant symptoms/ breathing is comfortable only at rest; yes, severe symptoms/ breathing is difficult even at rest).	2020-03-29	Upper respiratory	
Anosmia/Ageusia	Loss of smell/taste	2020-03-29	Central neurological	
Hoarse Voice	Unusually hoarse voice	2020-03-29	Upper respiratory	
Chest Pain	Unusual chest pain or tightness in your chest	2020-03-29	Cardiorespiratory	
Abdominal Pain	Unusual abdominal pain or stomach-ache	2020-03-29	Abdominal	
Diarrhoea	Diarrhoea	2020-03-29	Abdominal	
Delirium	Confusion, disorientation or drowsiness	2020-03-29	Central neurological	
Eye Soreness	Do your eyes have any unusual eye soreness or discomfort (e.g. light sensitivity, excessive tears, or pink/red eye)?	2020-04-29	Immune related/cutaneous	
Low appetite (anorexia)	Skipping meals	2020-04-29	Systemic/inflammatory	
Headache	Headache	2020-03-29	Central neurological	
Nausea	Nausea or vomiting	2020-03-29	Systemic/inflammatory	
Dizziness	Dizziness or light-headedness	2020-04-29	Systemic/inflammatory	
Sore Throat	Sore or painful throat	2020-03-29	Upper respiratory	
Myalgias	Unusual strong muscle pains or aches	2020-04-01	Systemic/inflammatory	

Red Welts	Raised, red, itchy welts on the skin or sudden swelling of the face or lips	2020-11-03	Immune related/cutaneous
Blisters	Red/purple sores or blisters on your feet, including your toes	2020-04-29	Immune related/cutaneous
Rashes	Rash on your arms or torso	2020-11-03	Immune related/cutaneous
Sensitive Skin	Strange, unpleasant sensations in your skin like pins & needles or burning	2020-11-03	Immune related/cutaneous
Hair Loss	Unusual hair loss	2020-11-03	Immune related/cutaneous
Low mood (depression)	Feeling down, depressed, or hopeless	2020-11-03	Central neurological
Brain Fog	Loss of concentration or memory (brain fog)	2020-11-03	Central neurological
Dysosmia/Dysgeusia	Altered smell/taste (things smell or taste different to usual)	2020-11-03	Central neurological
Rhinorrhoea	Runny nose	2020-11-03	Upper respiratory
Sneezing	Sneezing more than usual	2020-11-03	Upper respiratory
Ear Pain	Earache	2020-11-03	Upper respiratory
Tinnitus	Ringing in your ears	2020-11-03	Upper respiratory
Lymphadenopathy	Swollen neck glands	2020-11-03	Systemic/inflammatory
Palpitations	Unusually fast or irregular heartbeat (palpitations)	2020-11-03	Cardiorespiratory
Comorbidities			
Diabetes	Do you have diabetes?	2020-06-05	N/A
Cancer	Are you living with cancer?	2020-06-05	N/A
Lung Disease	Do you have lung disease or asthma?	2020-06-05	N/A
Heart Disease	Do you have heart disease?	2020-06-05	N/A
Kidney Disease	Do you have kidney disease?	2020-06-05	N/A

## Supplementary Table 2. List of questions from CSSB Long-COVID questionnaire included in the study.

Outcome	Question
Early Medical help	Q.B.5 In the <u>first 4 weeks</u> of illness, did you look for any medical help for any symptoms you think may have been caused by COVID-19?
Delayed Medical help	Q.B.6 Did you look for any medical help for any symptoms you had <u>more than 4</u> weeks after your symptoms began, that you think may have been caused by COVID-19?
Hospitalisation	Q.B.7 Have you ever had to stay in hospital because of COVID-19 symptoms?
Re-infection	Q.B.8 Do you think you have caught COVID-19 more than once?
Severe impact on daily activities	Q.B.13 How many days were you or have you been so unwell that you stayed in bed or on the sofa?
Prolonged impact in daily activities	Q.B.16 Thinking of how you felt 12 weeks after your COVID-19 illness began, what did you need help with because of COVID-19?

Supplementary Table 3. Symptoms prevalence for vaccinated and unvaccinated populations, per SARS-CoV-2 variant. Mann-Whitney two-sided test was used to assess the differences between the two groups, per variant of the virus. Alpha = 0.05, before multiple corrections. Bold encode significant differences, after multiple corrections (alpha corrected = 0.001).

		Alpł	na Variant		Delta Variant			
Symptoms	Statistics (vaccinate d)	p- value	Number vaccinate d	Number unvaccinate d	Statistics (vaccinate d)	p- value	Number vaccinate d	Number unvaccinate d
Persistent		0.33	118	720		0.45		
Cough	40111	1			177844	2	3798	98
Dizziness		0.06	114	670		0.97		
	33993	0			105051	7	2924	72
Palpitations		0.99	44	250		0.41		
_	5503.5	5			9629.5	2	930	23
Dyspnoea		0.66	85	555		0.17		
	24284.5	1			60218	4	2318	58
Chest Pain		0.03	82	478		0.15		
	16781	7			63531.5	9	1914	60
Hoarse voice		0.80	95	476		0.95		
	22247.5	5			83509.5	3	2726	61
Sore throat		0.03	126	690		0.69		
	38185.5	0			157143	0	3485	88
Eyes		0.70	76	469		0.51		
soreness	18304	5			67597.5	4	2258	57

Rhinorrhoea	c2204.5	0.02	176	798	261605	0.07	4727	100
C	62384.5	0 01	146	668	261685	2	4737	100
Sneezing	48494	0.91 6			146331	0.36 0	4224	65
Earache	6696	0.90 5	48	276	18323.5	0.41 6	1493	27
Tinnitus		0.29	63	340		0.52		
	11606.5	1	4.0=	10.11	26404.5	9	1764	28
Fatigue	103894.5	0.81	197	1066	354136	0.05 7	5076	127
Delirium		0.24	39	254		0.95		
	4378.5	0			18204.5	1	1145	32
Dysomnia	39057.5	0.09	116	746	179083	0.96 4	3741	96
Anosmia		0.08	80	546		0.71		
	24461	3			225144	8	4124	107
Headache		0.48	179	994		0.08		
	86060	7			290022.5	5	4730	112
Brain Fog	26892.5	0.32 7	100	573	86311.5	0.79 1	2775	61
Depression		0.16	78	477		0.35		
_	16766	1			51245	0	1903	50
Diarrhoea	11917	0.25 8	61	429	38476	0.31	1606	44
Abdominal	11717	0.93	61	375	36470	0.62	1000	44
Pain	11516.5	1	01	373	28416.5	3	1488	40
Low appetite		0.74	68	525		0.74		-
11	18279	7			49685	1	1855	55
Nausea		0.38	58	433		0.86		
	11675	4			37538.5	0	1555	49
Fever		0.05	81	594		0.15		
C1 '11	20896.5	4	100	C1.4	84154.5	0	2519	74
Chills	29242	0.05	108	614	71272 5	0.32	2661	<b>5</b> 0
Blisters	29242	0.13	8	32	71373.5	0.09	2661	58
Diisters	84	9	0	32	77.5	5	118	3
Red Welts	0-7	0.54	9	100	11.5	0.19	110	3
red weits	504.5	9		100	1557.5	3	307	8
Lymphopathi		0.10	46	281		0.17		
a	5496.5	3			22497	5	1398	37
Rash		0.35	19	125		0.99		
	1343.5	6			2637	2	351	15
Myalgias		0.81	82	582		0.34		
~	24250	1			71218	8	2148	62
Skin Burning	4640.5	0.24	28	293	12260	0.22	0.66	27
IIain lass	4649.5	1 0.76	10	50	13268	7	866	27
Hair loss	277	0.76 5	10	59	1456.5	0.95 9	245	12


**Supplementary Table 4. Illness description for the post-COVID syndrome across clusters and variants**. Clusters are labelled according to the profile found with the unsupervised algorithm. The number of individuals used to optimise the clusters within a variant (training sample) and the number of individuals classified with each cluster are presented. Median duration, in weeks, and interquartile range [IQR] presented per variant and optimised cluster. Main features and symptoms describe the highest ranked symptoms per cluster, based on z-scores values.

SARS- CoV-2 variant	Clusters	Number individuals	Duration (weeks)	Main features and symptoms	Classification
Wild	wild-A	138	24.0 [15.0; 40.8]	<ul> <li>Symptoms groups: cardiorespiratory, central neurological (anosmia) and upper respiratory (dyspnoea).</li> <li>High prevalence of dysosmia.</li> <li>Persistent cough as the most relevant symptom (highest z-score).</li> </ul>	Predominantly cardiorespiratory
	wild-B	60	27.5 [15.0; 48.3]	<ul> <li>Symptoms groups: systemic/inflammatory, central neurological, upper respiratory, and immune-related/cutaneous.</li> <li>Severe symptoms, namely severe dyspnoea for longer than 8 weeks.</li> <li>High prevalence of systemic symptoms.</li> <li>Unique cluster with immune-related symptoms.</li> <li>Most heterogeneous cluster.</li> </ul>	Systemic/inflam matory
	wild-C	38	15.0 [13.0; 30.8]	<ul> <li>Symptoms groups: upper respiratory, central neurological and systemic/inflammatory.</li> <li>Hoarse voice as the most relevant symptom (highest z-score).</li> <li>High prevalence of dysosmia, with almost neglectable z-score.</li> </ul>	Predominantly respiratory
	wild-D	37	22.0 [15.0; 49.0]	<ul> <li>Symptoms groups: upper respiratory, central neurological and abdominal.</li> <li>Diarrhoea and sore throat are the most relevant symptoms (highest z-score).</li> <li>High prevalence of neurological symptoms.</li> </ul>	Predominantly central neurological with abdominal
	Overall	273	23.0 [15.0; 43.0]	<ul> <li>Three main clusters: (1) with cardiorespiratory symptoms, (2) systemic/inflammatory and (3) central neurological.</li> <li>Abdominal and cutaneous symptoms isolated in singular clusters, with high relevance but lower prevalence.</li> </ul>	
Alpha	alpha-A	43	18.0 [14.0; 35.0]	<ul> <li>Symptoms groups: upper respiratory, central neurological and cardiorespiratory.</li> <li>Anosmia is the most relevant symptom.</li> <li>High prevalence of central neurological symptoms.</li> </ul>	Central neurological


alpha-B	28	16.5 [14.0; 28.8]	0	Symptoms groups: upper respiratory, central neurological and cardiorespiratory.  Persistent cough is the most relevant symptom, followed by dyspnoea.  High prevalence of respiratory symptoms and persistent cough.	Predominantly upper respiratory with cardiorespiratory.
alpha-C	23	22.0 [15.5; 55.0]	0 0	Symptoms groups: upper respiratory, central neurological, systemic/inflammatory and abdominal.  Strong relevance of respiratory symptoms, followed by systemic symptoms.  High prevalence of respiratory symptoms and persistent cough.	Predominantly upper respiratory with systemic.
alpha-D	17	17.0 [14.0; 43.0]	0	Symptoms groups: upper respiratory, systemic/inflammatory and immune-related/cutaneous.  Strong relevance of respiratory symptoms, followed by immune-related symptoms.  High prevalence of systemic and immune-related symptoms.	Predominantly immune-related/cutaneous with systemic.
alpha-E	16	23.0 [13.7; 41.0]	0 0 0	Symptoms groups: upper respiratory, systemic/inflammatory, immunerelated/cutaneous, cardiorespiratory and central neurological.  Strong relevance of immunerelated symptoms, namely blisters. High prevalence of mild fatigue. Highly heterogeneous cluster.	Predominantly mild symptoms.
alpha-F	15	18.0 [14.5; 37.5]	0 0	Symptoms groups: upper respiratory, systemic/inflammatory, abdominal and central neurological.  Strong relevance of systemic/inflammatory followed by neurological.  High prevalence of central neurological and systemic symptoms.	Predominantly central neurological with systemic/inflamm atory.
alpha-G	13	21.0 [15.0; 44.0]	0	Symptoms groups: upper respiratory, systemic/inflammatory, immunerelated, abdominal and cardiorespiratory.  Strong relevance of cardiorespiratory, followed by immune-related symptoms.  High prevalence of cardiorespiratory symptoms.	Multi-systemic with the predominance of cardiorespiratory symptoms.
Overall	155	18.0 [14.0; 43.5]	0	Three main clusters: (1) with cardiorespiratory symptoms, (2) systemic/inflammatory and	

	ı	1	1			
					immune-related and (3) central neurological.  Abdominal symptoms influence mostly the smaller cluster and immune-related symptoms are highly prevalent in clusters with systemic symptoms.	
Delta	v-delta- A	431	18.0 [14.0; 24.0]	0 0	Symptoms groups: central neurological.  Strong relevance of anosmia with high prevalence.	Central neurological
	v-delta-B	142	19.0 [14.0; 23.8]	0 0	Symptoms groups: upper respiratory, systemic/inflammatory, immunerelated, and central neurological. Strong relevance immune-related symptoms, namely blisters. High prevalence of upper respiratory and central neurological symptoms.	Predominantly upper respiratory with central neurological.
	v-delta- C	123	18.0 [14.0; 23.0]	0	Symptoms groups: upper respiratory, systemic/inflammatory, central neurological and cardiorespiratory. Strong relevance of upper respiratory, followed by cardiorespiratory. High prevalence of mild fatigue.	Multi-systemic with a predominance of mild fatigue, upper respiratory and headache.
	v-delta- D	107	20.0 [16.0; 25.0]	0	Symptoms groups: upper respiratory, systemic/inflammatory, central neurological and immunerelated/cutaneous.  Strong relevance of immunerelated, followed by systemic/inflammatory.  High prevalence of mild fatigue and neurological symptoms.	Predominantly immune-related with central neurological and systemic.
	v-delta- E	80	20.0 [16.8; 28.3]	0	Symptoms groups: upper respiratory, systemic/inflammatory, immune-related/cutaneous, abdominal and cardiorespiratory.  Strong influence of cardiorespiratory symptoms and severe dyspnoea.  High prevalence of mild fatigue and neurological symptoms.	Severe symptoms
	Overall	155	19.0 [15.0; 24.0]	0	Three main clusters: (1) with cardiorespiratory symptoms – severe symptoms, (2) systemic/inflammatory and immune-related and (3) central neurological.  Abdominal symptoms influence mostly the smaller cluster and immune-related symptoms are highly prevalent in clusters with systemic symptoms.	


Supplementary Figure 1. SARS-CoV-2 variants of concern in the UK by weeks, from 15<sup>th</sup> of March 2020 to 3<sup>rd</sup> of March 2022. Figure adapted from COG-UK/Mutation Explorer<sup>32</sup>. The variant periods are defined when the prevalence of the variant is higher than 80%. Variant sub-lineages are neglected and analysed as a single variant.




Supplementary Figure 2. Optimisation of BIC to select the best number of clusters per SARS-CoV-2 variant. A: Bootstrapping analysis for 50 randomly selected populations for training and testing set, for wild-type variant. B: Bootstrapping analysis for 20 randomly selected populations for training for alpha (left panel) and delta (right panel) variants. Panel B assesses the robustness of the optimised number of clusters. Given early convergence and a smaller sample to bootstrap (small sample size of CSSB sample with both alpha- and delta variants), only 20 runs were performed. No formal testing was performed for these samples.




Supplementary Figure 3. Significance analysis of symptoms profiles per cluster for the wild-type variant of the virus, for symptomatic disease longer than 12 weeks.




Supplementary Figure 4. Demographic profile per cluster for the wild-type variant of the virus, for symptomatic disease longer than 12 weeks. A: Body Mass Index (BMI) in kg/m<sup>2</sup>; B: Age in years. The diamond (\*) encodes outliers. Mann-Whitney test was conducted to assess statistical differences, alpha = 0.05.




Supplementary Figure 5. Individual profile for the clusters optimised for the wild-type variant for subjects with the symptomatic disease for longer than 12 weeks. The duration of each symptom is presented by the colour bar. The grey dots encode the average duration of each symptom for the population labelled with each cluster. The gradient colours encode the prevalence of the symptoms per week – darker encodes a higher prevalence of the symptom.




Supplementary Figure 6. Significance analysis of symptoms profiles per cluster for the alpha variant of the virus, for symptomatic disease longer than 12 weeks.




Supplementary Figure 7. Individual profile for the clusters optimised for the unvaccinated alpha variant for subjects with the symptomatic disease for longer than 12 weeks. The duration of each symptom is presented by the colour bar. The grey dots encode the average duration of each symptom for the population labelled with each cluster. The gradient colours encode the prevalence of the symptoms per week – darker encodes a higher prevalence of the symptom.



Supplementary Figure 8. Demographic profile per cluster for the unvaccinated alpha variant of the virus, for symptomatic disease longer than 12 weeks. A: Body Max Index (BMI) in  $kg/m^2$ ; B: Age in years. The diamond ( $\bullet$ ) encodes outliers. Mann-Whitney test was conducted to assess statistical differences, alpha = 0.05.




Supplementary Figure 9. Significance analysis of symptoms profiles per cluster for the vaccinated delta variant of the virus, for symptomatic disease longer than 12 weeks, for vaccinated subjects.




Supplementary Figure 10. Individual profile for the clusters optimised for vaccinated delta variant for subjects, who were infected after vaccination, with symptomatic lasting for longer than 12 weeks. The duration of each symptom is presented by the coloured bar. The grey dots encode the average duration of each symptom for the population labelled with each cluster. The gradient colours encode the prevalence of the symptoms per week – darker encodes a higher prevalence of the symptom.





Supplementary Figure 11. Demographic profile per cluster for the vaccinated delta variant of the virus, for symptomatic disease longer than 12 weeks. A: Body Max Index (BMI) in  $kg/m^2$ ; B: Age in years. The diamond (\*) encodes outliers. Mann-Whitney test was conducted to assess statistical differences, alpha = 0.05. Asterisk (\*) denotes statistical significance.



## Supplementary Figure 12. Comorbidity profile per cluster for the three variants of the virus, for symptomatic disease longer than 12 weeks.







Supplementary Figure 13. Similarity matrix between the symptom profile of the predicted clusters (wild-type variant) and the symptom profile of training set (wild-type variant). Median ratio of individuals reporting a symptom across illness is used to identify the top symptoms per cluster in the testing set (right column). The Euclidian distance between the top four (20%) symptom profile per testing cluster and equivalent symptom profile per training cluster is computed as similarity measure. Small differences identify the best matching symptom profile during the illness.

